RxDoctor Payments Data

Valerie Burkhard, MD

Urology · Orchard Park, NYNPI 1275709164

Payments from drug & device makers

$3,711in general payments, 2019–2025

Across 123 payments — averaging $30.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Axonics, Inc.$1K
  • Astellas Pharma US Inc$669
  • AbbVie$345
  • Endo Pharmaceuticals Inc.$321
  • Calyxo, Inc.$233
  • Medtronic$215
  • plus $609 from 13 others

What the payments were for

  • Travel & lodging$69519%
  • Food & beverage$2,80976%
  • Education$2076%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,711 in reported general payments places this provider in the 55th percentile of 952 urology providers in New York.

See all urology providers in New York

Medicare billing

Part B allowed, 2024
$151,842
Medicare patients
526
Services billed
3,972

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron282$181,630
GemtesaVibegron131$91,809
Mirabegron ErMirabegron39$23,289
Trospium Chloride ErTrospium Chloride82$10,747
Estradiol72$4,603
Solifenacin Succinate48$3,546
Cefdinir231$2,290
Trospium Chloride41$1,571
Cephalexin255$1,459
NitrofurantoinNitrofurantoin Macrocrystal71$1,134
Oxybutynin Chloride ErOxybutynin Chloride59$771
Cefpodoxime Proxetil15$767
Tamsulosin Hcl63$629
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst51$578
Ciprofloxacin Hcl66$291

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$669$181,630282 claims
Sumitomo Pharma America, Inc.Gemtesa$19$91,809131 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 952 urology providers in New York.

Other urology in Orchard Park

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →